Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection
- PMID: 37515399
- DOI: 10.1111/apt.17654
Incidence of hepatocellular carcinoma and mortality in chronic viral hepatitis in an Asian population with and without HIV infection
Abstract
Background: It is uncertain whether people with HIV infection have a higher incidence of hepatocellular carcinoma (HCC) than the general population.
Aims: To compare the incidence of HCC between people infected with HBV and/or HCV with and without HIV METHODS: We performed a retrospective population-based cohort study, involving people with HBV and/or HCV infection from 2001 to 2018. The primary endpoint was incidence of HCC; secondary endpoint was all-cause mortality. We performed Cox proportional hazard regression models to estimate the hazard ratios (HR) of HIV for the primary and secondary endpoints.
Results: We identified 1374 people infected with HIV and 39,908 people without HIV with HBV and/or HCV infection. Among those with HIV, 654 (47.6%) had HBV, 649 (47.2%) HCV and 71 (5.2%) HBV-HCV-co-infection; they were younger, and had a higher prevalence of HCV and a lower prevalence of cirrhosis. The incidence rate estimates of HCC were, respectively, 1.5 (95% CI: 0.8-2.5) and 7.6 (95% CI 7.3-8.0) per 1000 person-years for those with and without HIV infection. Using multivariate Cox proportional hazard regression models, among people with HBV, HIV was associated with lower risk of HCC (adjusted HR: 0.376, 95% CI: 0.201-0.704, p = 0.01) and death (adjusted HR: 0.692, 95% CI: 0.552-0.867, p = 0.007). Risks of HCC were similar for HCV and HBV-HCV co-infection for people with and without HIV.
Conclusions: Among individuals with HBV infection, the Incidence of HCC was lower in those with HIV. For HCV infection, incidence of HCC was similar between those with and without HIV.
Keywords: antiviral treatment; cirrhosis; death; liver cancer.
© 2023 John Wiley & Sons Ltd.
Comment in
-
Letter: Rethinking the lower incidence of HCC in HIV-infected patients- A closer look at confounding factors.Aliment Pharmacol Ther. 2023 Nov;58(9):956-957. doi: 10.1111/apt.17689. Aliment Pharmacol Ther. 2023. PMID: 37831527 No abstract available.
-
Letter: Rethinking the lower incidence of HCC in HIV-infected patients-A closer look at confounding factors. Authors' reply.Aliment Pharmacol Ther. 2023 Nov;58(9):958-959. doi: 10.1111/apt.17713. Aliment Pharmacol Ther. 2023. PMID: 37831538 No abstract available.
References
REFERENCES
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-
- McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1(Suppl 1):4-13.
-
- Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014-1018.
-
- Silverberg MJ, Chao C, Leyden WA, Xu L, Horberg MA, Klein D, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551-2559.
-
- Kim HN. Chronic hepatitis B and HIV coinfection: a continuing challenge in the era of antiretroviral therapy. Curr Hepatol Rep. 2020;19(4):345-353.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical